Cancer and inequality: rural lung cancer patients and gene testing
☕ Includes a question for the family ↓
Cancer and inequalityPart of a story we are following · 2 articles · See every update
If you or someone you love lives in a rural area and has advanced lung cancer, there is a test worth knowing by name: molecular testing. It looks at the tumor’s genes to help guide treatment. Cancer and inequality show up here, because many rural patients are not getting it, but knowing it exists gives you a clear question to ask.
In a study of 8,259 rural Medicare patients aged 66 or older with advanced non-small cell lung cancer, about 1 in 3 (2,963 people) received molecular testing within six months of diagnosis.
How the study worked
Researchers used national cancer registry records linked to Medicare claims. They followed rural adults diagnosed with advanced non-small cell lung cancer between January 2014 and December 2019, from shortly before diagnosis until six months after. It was an observational cohort study, so it shows patterns and not cause and effect. It was published in JAMA Network Open on November 2, 2026.
What they found
Overall, 35.9% of patients had molecular testing. By 180 days after diagnosis, the share tested was about 36 out of every 100 patients. That means roughly 64 out of 100 did not have it recorded in this time.
Some groups were more likely to be tested than others:
- People diagnosed in later years were more likely to be tested.
- People enrolled in Medicare Part D, the drug coverage plan, were more likely to be tested.
- Older patients were somewhat less likely to be tested.
- People who also had Medicaid were less likely to be tested.
- People with squamous cell lung cancer, a type that looks different under the microscope, were much less likely to be tested.
Visits mattered too. Among tested patients with visit records, 77.7% had seen both a surgeon or a procedure specialist and a cancer doctor (an oncologist). Among patients who were not tested, that share was 58.9%.
The researchers describe testing as low in this group. They point to coverage and specialist care as areas to look at next to make lung cancer care fairer.
What is molecular testing?
Molecular testing checks a sample of the tumor for gene changes. Doctors in the US treat it as standard care for advanced non-small cell lung cancer. The results can help doctors choose among treatment options.
Think of it like reading the label on a lock before picking a key. The test does not treat the cancer itself. It gives your care team more information to work with.
What you can do today
If you or a family member has advanced lung cancer, ask the care team this one question at the next visit: “Has the tumor had molecular testing, and can we see the results?” If the answer is no, ask whether it can be done. Write the question on a card or in your phone so you have it ready.
Talk about it at home
Doctors can look at a tumor’s genes, a bit like reading the tiny label on a lock before choosing a key. That label helps the care team pick the treatment that fits best. Scientists looked at the records of many people living far from big cities, and they counted how often this gene check actually happened.
Question for the table
The scientists only looked at records and did not change anything for anyone. So how can we tell what they found is a pattern, and not proof that one thing caused another? Think of two kids who both carry umbrellas on rainy days: does the umbrella make the rain?
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Questions and answers
- What is molecular testing for lung cancer?
- It checks a sample of the tumor for gene changes. In the US it is standard care for advanced non-small cell lung cancer.
- How many rural patients in the study got tested?
- Of 8,259 rural Medicare patients, 2,963 (35.9%) received molecular testing.
- Does this study show why some patients were not tested?
- No. It was an observational study, so it shows patterns, such as links with Medicaid coverage, Part D enrollment and specialist visits, but not the reasons.
- What can I ask my care team?
- Ask whether the tumor has had molecular testing and whether you can see the results.
